Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use.

Peter Rossing,Rajiv Agarwal,Stefan D Anker,Gerasimos Filippatos,Bertram Pitt,Luis M Ruilope,Vivian Fonseca,Guillermo E Umpierrez,Maria Luiza Caramori,Amer Joseph,Marc Lambelet,Robert Lawatscheck,George L Bakris

Diabetes, obesity & metabolism（2023）

引用 4|浏览12

暂无评分

摘要

The cardiorenal benefits of finerenone on composite cardiovascular and kidney outcomes and UACR reduction in patients with CKD and T2D appear to be maintained, regardless of GLP-1RA use. Subsequent studies are needed to investigate any potential benefit of this combination.

查看译文

关键词

chronic kidney disease,diabetes,peptide‐1,receptor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要